49 results
PRE 14A
GLTO
Galecto Inc
16 Apr 24
Preliminary proxy
4:00pm
community. In practice, however, many
investors, brokerage firms and market makers consider low-priced stocks as unduly speculative in nature … officer or director, we will disclose the nature of such amendment or waiver on our website or in a current report on Form 8-K.
Hedging and Pledging
8-K
GLTO
Galecto Inc
21 Dec 23
Other Events
4:30pm
adverse events were gastrointestinal in nature and were manageable in most patients with standard therapy. The only treatment-related serious adverse
8-K
p4xhidvi o3vk
29 Sep 22
GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target
7:00am
8-K
EX-99.1
370apa4694wxi80fwcpd
29 Sep 22
GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target
7:00am
S-3
EX-4.4
e9b6k4y 9j
4 Nov 21
Shelf registration
4:59pm
S-3
EX-4.3
8zfw71tg bsi
4 Nov 21
Shelf registration
4:59pm